Sökning: onr:"21960848" >
Growth Differentiat...
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
-
Lindholm, Daniel P 1982- (författare)
-
Hagström, Emil (författare)
-
James, Stefan K 1964- (författare)
-
visa fler...
-
Becker, Richard C (författare)
-
Cannon, Christopher P (författare)
-
Himmelmann, Anders (författare)
-
Katus, Hugo A (författare)
-
Maurer, Gerald (författare)
-
López-Sendón, José Luis (författare)
-
Steg, Philippe Gabriel (författare)
-
Storey, Robert F (författare)
-
Siegbahn, Agneta 1947- (författare)
-
Wallentin, Lars 1943- (författare)
-
visa färre...
-
(utgivare)
-
(utgivare)
-
visa fler...
-
(utgivare)
-
visa färre...
- 2017
- 2017
- Engelska.
-
Ingår i: Journal of the American Heart Association. - 2047-9980. ; 6:4
Abstract
Ämnesord
Stäng
- BACKGROUND: Growth differentiation factor-15 (GDF-15) is related to major bleeding when measured at initial presentation in patients with acute coronary syndromes (ACSs) treated with dual antiplatelet therapy. It is unknown whether follow-up measurements provide additional information. The objective of this study was to investigate whether GDF-15 measured 1 month after an ACS provides additional information beyond the baseline levels with regard to the risk of major bleeding. METHODS AND RESULTS: GDF-15 was measured at baseline and at 1 month after an ACS in 4049 patients included in the PLATelet inhibition and patient Outcomes (PLATO) trial. The association between 1-month GDF-15 level and non-coronary artery bypass grafting surgery-related major bleeding was assessed by a multivariable Cox model, adjusting for baseline GDF-15, age, anemia, impaired renal function, history of gastrointestinal bleeding, and sex. Elevated GDF-15 (>1800 ng/L) at 1 month was associated with an increased risk of non-coronary artery bypass grafting-related major bleeding (3.9% versus 1.2%; hazard ratio, 3.38; 95% CI, 1.89-6.06), independent of baseline GDF-15. Patients who had elevated GDF-15 levels at baseline and subsequent nonelevated GDF-15 at 1 month had a similar risk as patients who had nonelevated levels at both measurements. CONCLUSIONS: GDF-15 at 1 month after an ACS is related to the risk of bleeding during DAPT and provides additional information on the bleeding risk beyond baseline GDF-15 levels. GDF-15 levels may therefore be useful as part of decision support concerning long-term antithrombotic treatment in patients post-ACS. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00391872.
Ämnesord
- Medical and Health Sciences (hsv)
- Clinical Medicine (hsv)
- Cardiac and Cardiovascular Systems (hsv)
- Medicin och hälsovetenskap (hsv)
- Klinisk medicin (hsv)
- Kardiologi (hsv)
- Cardiology (uu)
- Kardiologi (uu)
Nyckelord
- biomarker
- bleeding
- ischemic heart disease
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Lindholm, Daniel ...
-
Hagström, Emil
-
James, Stefan K ...
-
Becker, Richard ...
-
Cannon, Christop ...
-
Himmelmann, Ande ...
-
visa fler...
-
Katus, Hugo A
-
Maurer, Gerald
-
López-Sendón, Jo ...
-
Steg, Philippe G ...
-
Storey, Robert F
-
Siegbahn, Agneta ...
-
Wallentin, Lars ...
-
visa färre...
- Av lärosätet
-
Swepub_uni:_t